已核实 DOI PubMed 相关产品: 84

Fatty acid modification of antimicrobial peptide CGA-N9 and the combats against Candida albicans infection

Journal 2023 · IF 5.8 · 发表于 2023 年 4 月 3 日
作者: Ruifang Li,Xuxia Wang,Kedong Yin,Qingpeng Xu,Shiming Ren,Xueqin Wang,Zichao Wang,Yanjie Yi
阅读全文 在 PubMed 查看

摘要

High-efficiency and low-toxic antimicrobial peptides (AMPs) are supposed to be the future candidates to solve the increasingly prominent problems of Candida albicans infection and drug resistance. Generally, introduction of hydrophobic moieties on AMPs resulted in analogues with remarkably increased activity against pathogens. CGA-N9, an antifungal peptide found in our lab, is a Candida -selective antimicrobial peptide capable of preferentially killing Candida spp. relative to benign microorganisms with low toxicities. We speculate that fatty acid modification could improve the anti- Candida activity of CGA-N9. In the present investigation, a set of CGA-N9 analogues with fatty acid conjugations at N-terminus were obtained. The biological activities of CGA-N9 analogues were determined. The results showed that the n-octanoic acid conjugation of CGA-N9 (CGA-N9-C8) was the optimal CGA-N9 analogue with the highest anti- Candida activity and biosafety; exhibited the strongest biofilm inhibition activity and biofilm eradication ability; and the highest stability against protease hydrolysis in serum. Furthermore, CGA-N9-C8 is less prone to develop resistance for C. albicans in reference with fluconazole ; CGA-N9-C8 also exhibited Candidacidal activity to the planktonic cells and the persister cells of C. albicans ; reduced C. albicans susceptibility in a systemic candidiasis mouse model. In conclusion, fatty acid modification is an effective method to enhance the antimicrobial activity of CGA-N9, and CGA-N9-C8 is a promising candidate to defend C. albicans infection and resolve C. albicans drug resistance.

本研究中使用的阿拉丁产品

84 款产品在本文中被引用